Deerfield Management Company, L.P. (Series C) Vir Biotechnology, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $3.95 Billion
- Q1 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 15,728 shares of VIR stock, worth $70,776. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,728Holding current value
$70,776% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VIR
# of Institutions
255Shares Held
92.6MCall Options Held
257KPut Options Held
261K-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$75.1 Million0.99% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$74 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$57.6 Million0.0% of portfolio
-
State Street Corp Boston, MA5.73MShares$25.8 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.68MShares$12.1 Million0.0% of portfolio
About Vir Biotechnology, Inc.
- Ticker VIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 132,638,000
- Market Cap $597M
- Description
- Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...